Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study

• Status: Active, not recruiting
• Trial end date: 2021-09-01

Summary

The aim of this study is to determine the feasibility of running a phase III double-blind, double-dummy randomised controlled trial comparing Depo-Medrone 120mg intramuscular injection vs. Anakinra 100mg subcutaneous injection for 5 days for the treatment of acute gout attacks in patients with chronic kidney disease as defined by a eGFR < 60mls/min/1.73m2 and ≥ 30mls/min/1.73m2.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Mid and South Essex NHS Foundation Trust; Southend University Hospital Foundation NHS Trust
• Collaborators: Anglia Ruskin University; National Institute for Health Research, United Kingdom; University of East Anglia; University of Essex
• Treatments: Interleukin 1 Receptor Antagonist Protein; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate